The potential therapy with dental tissue-derived mesenchymal stem cells in Parkinson's disease

Stem Cell Res Ther. 2021 Jan 6;12(1):5. doi: 10.1186/s13287-020-01957-4.

Abstract

Parkinson's disease (PD), the second most common neurodegenerative disease worldwide, is caused by the loss of dopaminergic (DAergic) neurons in the substantia nigra resulting in a series of motor or non-motor disorders. Current treatment methods are unable to stop the progression of PD and may bring certain side effects. Cell replacement therapy has brought new hope for the treatment of PD. Recently, human dental tissue-derived mesenchymal stem cells have received extensive attention. Currently, dental pulp stem cells (DPSCs) and stem cells from human exfoliated deciduous teeth (SHED) are considered to have strong potential for the treatment of these neurodegenerative diseases. These cells are considered to be ideal cell sources for the treatment of PD on account of their unique characteristics, such as neural crest origin, immune rejection, and lack of ethical issues. In this review, we briefly describe the research investigating cell therapy for PD and discuss the application and progress of DPSCs and SHED in the treatment of PD. This review offers significant and comprehensive guidance for further clinical research on PD.

Keywords: Cell therapy; Dental pulp stem cells; Dopaminergic neurons; Parkinson’s disease; Stem cells from human exfoliated deciduous teeth.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cell Differentiation
  • Dental Pulp
  • Dopaminergic Neurons
  • Humans
  • Mesenchymal Stem Cells*
  • Neurodegenerative Diseases*
  • Parkinson Disease* / therapy
  • Tooth, Deciduous